This protocol provides a detailed approach to assessing m6A modification levels of specific RNA using MeRIP-qPCR.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
This protocol provides a detailed approach to assessing m6A modification levels of specific RNA using MeRIP-qPCR.
RNA epitranscriptomic modification plays a critical role in the initiation and development of various cancers, among which N6-methyladenosine (m6A) is the most prevalent and functionally diverse modification. Here, we present a streamlined and reproducible protocol using MeRIP-qPCR to assess m6A modification levels of specific transcripts in osteosarcoma cells. In this assay, total RNA was extracted, followed by incubation with a specific anti-m6A antibody to immunocapture RNA of m6A modification. Then, RNA was fragmented, and enrichment of m6A-modified RNA fragments was achieved using protein G magnetic beads. The enriched RNA was released by proteinase K digestion and purified by RNA-binding beads. Lastly, RNA was subjected to reverse transcription and quantitative polymerase chain reaction (PCR) to assess m6A levels in candidate genes. The results have demonstrated that this method effectively distinguishes methylation differences and provides a reliable tool for exploring the functional mechanisms of m6A modification in osteosarcoma cells. In conclusion, MeRIP-qPCR offers a simple and highly specific approach for studying m6A modification in osteosarcoma cells. This protocol holds great potential for elucidating m6A regulatory networks and identifying novel therapeutic targets.
The latest epitranscriptome research reveals that RNA N6-methyladenosine (m6A) modification, the methylation of N6 position on adenosine, is the most abundant known intrinsic chemical modification of mRNA in eukaryotic cells1. m6A is involved in a wide range of biological processes, including mRNA stability, splicing, nuclear export, and translation efficiency2. Importantly, accumulating evidence suggests that dysregulation of m6A modification contributes to the initiation and development of various cancers, including osteosarcoma, a highly aggressive malignant bone tumor that predominantly affects adolescents and young adults3.
The study of m6A modification requires robust and reliable methodologies. Several approaches have been developed to detect m6A modification levels, including m6A dot blot, m6A ELISA, and MeRIP-seq. The m6A dot blot assay is simple and cost-effective, yet it suffers from limited sensitivity and poor quantification. It provides the m6A modification level of total RNA, rather than the m6A modification level of a specific RNA4. m6A ELISA offers relatively convenient and high-throughput detection; however, cross-reactivity and low accuracy remain major concerns, and it similarly lacks the capacity to reveal transcript- or site-specific modifications5. MeRIP-seq enables transcriptome-wide mapping of m6A; however, its requirements for large RNA input, relatively low resolution, and antibody dependency limit MeRIP-seq precision and reproducibility6. By contrast, MeRIP-qPCR combines immunoprecipitation with quantitative PCR, providing higher sensitivity and specificity for targeted detection of m6A on specific RNA7. This method enables sensitive and targeted detection of differential m6A enrichment in candidate genes, making it particularly suitable for validation studies in m6A-related cancer research. This method offers a cost-effective and accessible alternative for laboratories aiming to investigate m6A-mediated regulatory mechanisms.
Here, we provided a detailed protocol (Figure 1) to assess m6A modification levels of c-Myc in osteosarcoma cells using MeRIP-qPCR as an example. MeRIP-qPCR, relying on antibody-based enrichment of methylated RNA fragments, also coupled with reverse transcription and quantitative PCR, evaluates the presence and relative abundance of m6A on specific RNA. We demonstrated that this approach effectively distinguished methylation differences of c-Myc and provided a reliable platform for investigating the functional role of m6A in osteosarcoma cells. This study highlights the potential of MeRIP-qPCR as a practical and specific tool for m6A modification research in osteosarcoma and sets the stage for identifying novel therapeutic targets.
Access restricted. Please log in or start a trial to view this content.
1. Preparing the RNA
NOTE: RNA Extraction is performed using an RNA extraction kit. Work inside a clean biosafety cabinet when handling cells and RNA reagents. Wear appropriate personal protective equipment (lab coat, gloves, protective eyewear). Pre-cool the centrifuge to 4 °C before starting.
2. Methylated RNA immunoprecipitation (MeRIP)
3. RT-qPCR
Access restricted. Please log in or start a trial to view this content.
Here we provide a representative result of MeRIP-qPCR analysis, the m6A modification level of c-Myc in hFOB1.19 and 143B cells. As shown in Figure 2, c-Myc enrichment with anti-m6A antibody was significantly higher compared to IgG control, which only showed background levels, suggesting that the anti-m6A antibody is both effective and specific. We also observed that the m6A modification level of c-Myc was significantly higher in 143B than in hFOB1....
Access restricted. Please log in or start a trial to view this content.
MeRIP-qPCR has emerged as a valuable tool for studying RNA m6A modifications with broad applications. It is particularly useful in validating high-throughput sequencing results and localizing modification sites precisely within specific regions of target genes during mechanistic studies. Furthermore, this method can be readily implemented in most molecular biology laboratories due to its relatively low cost and operational simplicity, making it an efficient and practical approach for epitranscriptomic research...
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This study was supported by grants from National Nature Science Foundation (82174408, 82374477, 82474535 and 82205145).
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 100% ethanol | Shanghai Titan Scientific Co.,Ltd., America | 1158566 | |
| 143B | ATCC, America | ATCC CRL-8303TM | |
| 2×SYBR Green qPCR Mix | Beijing Qihengxing Biotechnology Co., Ltd., China | FS-Q1002 | |
| Denovix DS-11 | Denovix | DS-11 | Spectrophotometer |
| DMEM medium | WISENT CORPORATION, China | 319-005-CL | |
| DMEM/F-12 medium | Gibco, America | 11320033 | |
| EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit | Epigentek, America | P-9018-24 | |
| Fetal Bovine Serum | WISENT CORPORATION, China | 086-150 | |
| hFOB1.19 | Cell Bank of the Chinese Academy of Sciences, China | GNHu14 | |
| m6A RNA Methylation Assay Kit | Abcam, England | ab185912 | |
| microRNA Reverse Transcription Kit | EZBioscience-EZB, America | A0010CGQ | |
| Real-Time System | BIO-RAD, America | CFX96 | |
| Total RNA Extraction Kit | EZBioscience-EZB, America | B0004DP | |
| TrypLE Express Enzyme | Gibco, America | 12604021 |
Access restricted. Please log in or start a trial to view this content.